Company: BrainStorm Cell Therapeutics
Drug Type: Stem Cell Therapy
Conditions: ALS, multiple sclerosis, Parkinson’s disease, Huntington’s disease.
Mechanism Type: Neuroprotection
Mechanism: NurOwn is an experimental cell-based therapy containing autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors including BDNF, GDNF and HGF, as a possible treatment for patients with ALS.
U.S. Status for ALS: Phase III
 Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Petrou P et al. JAMA Neurol. 2016 Mar;73(3):337-44.
 Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (NurOwn). ClinicalTrials.gov, 13 Jan 2016. Accessed 9 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02017912.
Last updated February 8th, 2018